Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression

Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression

BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading cancer death in the United States, and also one of the major cancer-related deaths in Chinese. Androgen deprivation therapy (ADT) is the first line treatment for metastatic PCa. PCa ultimately relapse...

Full description

Bibliographic Details
Main Authors: Chou, Yu-Wei, Lin, Fen-Fen, Muniyan, Sakthivel, Lin, Frank C., Chen, Ching-Shih, Wang, Jue, Huang, Chao-Cheng, Lin, Ming-Fong
Other Authors: Tissue Bank and BioBank, Kaohsiung Chang Gung Memorial Hospital
Language:en
Published: BioMed Central 2015
Subjects:
Prostate cancer
Histone deacetylase inhibitor
Cellular prostatic acid phosphatase
Biomarker
Online Access:http://hdl.handle.net/10150/610307
http://arizona.openrepository.com/arizona/handle/10150/610307

Internet

http://hdl.handle.net/10150/610307
http://arizona.openrepository.com/arizona/handle/10150/610307

Similar Items